StocksMedium•4 November 2026•
1 min read
Zydus Lifesciences Q2 Profit Drops 26.6% as Expenses Surge
Key Facts
1Zydus Lifesciences reported a 26.6% decline in consolidated net profit to ₹925.5 crore for the September quarter.
2Revenue from operations increased to ₹7,909.6 crore compared to ₹6,123.2 crore in the corresponding period last year.
3Total expenses rose sharply to ₹6,806.6 crore from ₹4,509 crore in the previous year.
Zydus Lifesciences reported a 26.6% decline in consolidated net profit to ₹925.5 crore for the quarter ended September. Business Standard reported that revenue from operations increased to ₹7,909.6 crore from ₹6,123.2 crore in the corresponding period last year, though this growth was offset by rising costs.
Total expenses for the company rose sharply to ₹6,806.6 crore from ₹4,509 crore in the previous year. According to company filings, the pharmaceutical business contributed 83% of sales, with India formulations growing by 18% and North America formulations by 21%, while Zydus Lifesciences shares were trading lower on November 4, 2026.